ClinicalTrials.gg
CompletedNCT05669599Updated Jan 20, 2026

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

A Phase 2 interventional study of Maridebart Cafraglutide and Placebo in Obesity, Overweight and Type 2 Diabetes Mellitus, sponsored by Amgen. Completed at 78 sites in 12 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2024, 2 years 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Feb 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
592
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing maridebart cafraglutide in Obesity — 9 open to participants now, 17 under way, 11 of them phase 3. maridebart cafraglutide · Obesity.

Enrollment
8th of 28
592 · median 275
Started
2023
the only one that year
Phase 2
3 of 28
none open now
Registered
2nd of 28
by date
Lead sponsor
28 of 28
Amgen

Among the 28 studies testing maridebart cafraglutide in Obesity, this one is the 8th largest by enrollment, is the only one that started in 2023, is one of 3 in phase 2, and was the 2nd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 28 studies testing maridebart cafraglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About maridebart cafraglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing maridebart cafraglutide in Obesity, or all of them as a file.
02

Study summary

The study aims to compare and assess the dose response of 3 selected doses of maridebart cafraglutide compared with placebo, on inducing and maintaining weight loss from baseline at Week 52 in participants with overweight or obesity without diabetes mellitus (Cohort A) and in participants with overweight or obesity with Type 2 diabetes mellitus (Cohort B).

03

Conditions studied

  • Obesity
  • Overweight
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years at the time of signing .
  • ≥30 kg/m\^2, or ≥27 kg/m\^2 and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease.
  • For participants in cohort B only, ≥ 7% and ≤ 10% (53 to 86 mmol/mol) at screening with an established diagnosis of type 2 diabetes mellitus for ≥ 180 days prior to screening and either treated with diet and exercise alone or on stable (at least 90 days prior to screening) treatment with metformin, a sulfonylurea, or a sodium-glucose cotransporter 2 (SGLT2) inhibitor as monotherapy or combination therapy, per approved local label.
  • History of at least one unsuccessful dietary effort to lose body weight.

Exclusion criteria

Exclusion Criteria:

  • Change in body weight greater than 5 kg within 3 months prior to screening.
  • Obesity induced by other endocrinologic disorders.
  • History of pancreatitis.
  • Family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN-2).
  • History of major depressive disorder within the last 2 years.
  • Any lifetime history of other major psychiatric disorder or suicide attempt.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
592 participants (actual)

Study arms

  • Experimental
    Cohort A: Maridebart Cafraglutide

    Part 1: Cohort A will consist of participants without a diagnosis of type 1 or type 2 diabetes mellitus. Participants will be randomized to receive maridebart cafraglutide or placebo in 1 of 7 dose cohorts. Participants will then have the option to begin part 2 if they meet the entry criteria. Part 2: Participants that continue into part 2 will be re-randomized to receive maridebart cafraglutide or Placebo in 1 of 4 dose cohorts.

    Biological: Maridebart Cafraglutide · Drug: Placebo

  • Placebo comparator
    Cohort A: Placebo

    Part 1: Cohort A will consist of participants without a diagnosis of type 1 or type 2 diabetes mellitus. Participants will be randomized to receive maridebart cafraglutide or placebo in 1 of 7 dose cohorts . Participants will then have the option to begin part 2 if they meet the entry criteria. Part 2: Participants that continue into part 2 will be re-randomized to receive maridebart cafraglutide or Placebo in 1 of 4 dose cohorts.

    Biological: Maridebart Cafraglutide · Drug: Placebo

  • Experimental
    Cohort B: Maridebart Cafraglutide

    Part 1: Cohort B will consist of participants with a diagnosis of type 2 diabetes mellitus. Participants will be randomized to receive maridebart cafraglutide or placebo in 1 of 4 dose cohorts. Participants will then have the option to begin part 2 if they meet the entry criteria. Part 2: Participants that continue into part 2 will be re-randomized to receive maridebart cafraglutide or Placebo in 1 of 4 dose cohorts.

    Biological: Maridebart Cafraglutide · Drug: Placebo

  • Placebo comparator
    Cohort B: Placebo

    Part 1: Cohort B will consist of participants with a diagnosis of type 2 diabetes mellitus. Participants will be randomized to receive maridebart cafraglutide or placebo in 1 of 4 dose cohorts. Participants will then have the option to begin part 2 if they meet the entry criteria. Part 2: Participants that continue into part 2 will be re-randomized to receive maridebart cafraglutide or Placebo in 1 of 4 dose cohorts.

    Biological: Maridebart Cafraglutide · Drug: Placebo

Interventions

  • Participants will receive maridebart cafraglutide by subcutaneous (SC) injection.

    Also known as: AMG 133

  • DrugPlacebo

    Participants will receive placebo by SC injection.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Week 52 in Body Weight

    Time frame: Baseline and Week 52

Secondary outcomes

  1. Percentage of Participants Achieving ≥ 5% Reduction in Body Weight From Baseline at Week 52

    Time frame: Baseline and Week 52

  2. Percentage of Participants Achieving ≥ 10% Reduction in Body Weight From Baseline at Week 52

    Time frame: Baseline and Week 52

  3. Achievement of ≥ 15% Reduction in Body Weight From Baseline at Week 52

    Time frame: Baseline and Week 52

  4. Achievement of ≥ 20% Reduction in Body Weight From Baseline at Week 52

    Time frame: Baseline and Week 52

  5. Change from Baseline to Week 52 in Hemoglobin A1c (HbA1c)

    Time frame: Baseline and Week 52

  6. Change from Baseline to Week 52 in Fasting Serum Insulin

    Time frame: Baseline and Week 52

  7. Change from Baseline to Week 52 in Fasting Plasma Glucose

    Time frame: Baseline and Week 52

  8. Change from Baseline to Week 52 in Homeostasis Model Assessment for Insulin Resistance (HOMA2-IR)

    Time frame: Baseline and Week 52

  9. Change from Baseline to Week 52 in Homeostasis Model Assessment for Steady State Beta Cell Function (HOMA2-%B)

    Time frame: Baseline and Week 52

  10. Maximum Observed Plasma Concentration (Cmax) of maridebart cafraglutide

    Time frame: Up to Week 64

  11. Area Under the Concentration-time Curve (AUC) of maridebart cafraglutide

    Time frame: Up to Week 64

  12. Change from Baseline to Week 52 in Waist Circumference

    Time frame: Baseline and Week 52

  13. Change from Baseline to Week 52 in Body Weight

    Time frame: Baseline and Week 52

  14. Change from Baseline to Week 52 in Systolic Blood Pressure (SBP)

    Time frame: Baseline and Week 52

  15. Change from Baseline to Week 52 in Diastolic Blood Pressure (DBP)

    Time frame: Baseline and Week 52

  16. Change from Baseline to Week 52 in Body Fat Mass Using Dual-energy X-ray Absorptiometry (DEXA)

    Analyzed in a subset of participants.

    Time frame: Baseline and Week 52

  17. Change from Baseline to Week 52 in Lean Body Mass Using DEXA

    Analyzed in a subset of participants.

    Time frame: Baseline and Week 52

  18. Percent Change From Baseline to Week 52 in High-sensitivity C-reactive Protein (hs-CRP)

    Time frame: Baseline and Week 52

  19. Change from Baseline to Week 52 in Body Mass Index (BMI)

    Time frame: Baseline and Week 52

  20. Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

    Time frame: Baseline and Week 52

  21. Percent Change From Baseline in Total Cholesterol

    Time frame: Baseline and Week 52

  22. Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)

    Time frame: Baseline and Week 52

  23. Percent Change From Baseline in non-HDL-C

    Time frame: Baseline and Week 52

  24. Percent Change From Baseline in Very-low-density Lipoprotein Cholesterol (VLDL-C)

    Time frame: Baseline and Week 52

  25. Percent Change From Baseline in Triglycerides

    Time frame: Baseline and Week 52

  26. Percent Change From Baseline in Free Fatty Acids (FFA)

    Time frame: Baseline and Week 52

07

Study locations

78 sites
  • Alliance for Multispecialty Research Mobile
    Mobile, Alabama 36608, United States
  • Foothills Research Center
    Phoenix, Arizona 85044, United States
  • HonorHealth
    Scottsdale, Arizona 85258, United States
  • Ark Clinical Research- Long Beach
    Long Beach, California 90815, United States
  • Ark Clinical Research- Tustin
    Tustin, California 92780, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Diablo Clinical Research
    Walnut Creek, California 94598, United States
  • Alliance for Multispecialty Research Miami
    Coral Gables, Florida 33134, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • East-West Medical Research
    Honolulu, Hawaii 96814, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • Alliance for Multispecialty Research Newton
    Newton, Kansas 67114, United States
  • Louisville Metabolic and Atherosclerosis Research Center
    Louisville, Kentucky 40213, United States
  • Tandem Clinical Research - Marrero
    Marrero, Louisiana 70072, United States
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
  • Alliance for Multispecialty Research Kansas City
    Kansas City, Missouri 64114, United States
  • State University of New York Upstate Medical University
    Syracuse, New York 13210, United States
  • Lucas Research
    Morehead City, North Carolina 28557, United States
  • Research Innovations LLC dba Internal Medicine Care Inc
    Beavercreek, Ohio 45431, United States
  • The Christ Hospital
    Cincinnati, Ohio 45219, United States
  • Alliance for Multispecialty Research Norman
    Norman, Oklahoma 73069, United States
  • Medical Care LLC
    Elizabethton, Tennessee 37643, United States
  • PanAmerican Clinical Research LLC
    Brownsville, Texas 78520, United States
  • Headlands Research Brownsville
    Brownsville, Texas 78526, United States
  • Clinical Trials of Texas
    San Antonio, Texas 78229, United States
  • Diabetes and Glandular Disease Clinic
    San Antonio, Texas 78229, United States
  • Pinnacle Clinical Research
    San Antonio, Texas 78229, United States
  • Texas Diabetes Institute
    San Antonio, Texas 78284, United States
  • Royal Prince Alfred Hospital (RPAH) Clinic
    Camperdown, New South Wales 2006, Australia
  • Clinical Medical and Analytical eXellence CMAX
    Adelaide, South Australia 5000, Australia
  • Monash Medical Centre
    Clayton, Victoria 3146, Australia
  • St Vincents Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
  • Austin Health, Heidelberg Repatriation Hospital
    Heidelberg Heights, Victoria 3081, Australia
  • Baker Heart and Diabetes Institute
    Melbourne, Victoria 3004, Australia
  • University of Calgary
    Calgary, Alberta T2T 5C7, Canada
  • Centricity Research Brampton Endocrinology
    Brampton, Ontario L6S 0C6, Canada
  • Centricity Research Vaughan Endocrinology
    Concord, Ontario L4K 4M2, Canada
  • Institut Universitaire de cardiologie et de pneumologie de Quebec
    Québec, Quebec G1V 4G5, Canada
  • Clinique des Maladies Lipidiques de Quebec Incorporated
    Québec, Quebec G1V 4W2, Canada
  • Endokrinologicky ustav
    Prague, 116 94, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Prague, 128 08, Czechia
  • Institut klinicke a experimentalni mediciny
    Prague, 140 21, Czechia
  • Charite - Universitaetsmedizin Berlin, Campus Mitte
    Berlin, 10117, Germany
  • Diabeteszentrum Hamburg West
    Hamburg, 22607, Germany
  • Universitaetsmedizin Leipzig
    Leipzig, 04103, Germany
  • Prince of Wales Hospital
    Shatin, New Territories, Hong Kong
  • Budapesti Szent Ferenc Korhaz
    Budapest, 1021, Hungary
  • Clinexpert Kft
    Budapest, 1033, Hungary
  • CRU Hungary Kft
    Encs, 3860, Hungary
  • Pecsi Tudomanyegyetem Klinikai Kozpont
    Pécs, 7624, Hungary
  • Mikannohana Clinic, Diabetes, Endocrinology and Metabolism
    Matsuyama, Ehime 790-0034, Japan
  • Wellness Tenjin Clinic
    Fukuoka, Fukuoka 810-0001, Japan
  • Matsunami Health Promotion Clinic
    Hashima-gun, Gifu 501-6061, Japan
  • Mazda Hospital of Mazda Motor Corporation
    Aki-gun, Hiroshima 735-8585, Japan
  • Nakakinen Clinic
    Naka, Ibaraki 311-0113, Japan
  • Nishiyamado Keiwa Hospital
    Naka, Ibaraki 311-0133, Japan
  • Shiraiwa Medical Clinic
    Kashiwara-shi, Osaka 582-0005, Japan
  • Nihonbashi Sakura Clinic
    Chuo-ku, Tokyo 103-0025, Japan
  • MIH Clinic Yoyogi
    Shibuya-ku, Tokyo 151-0051, Japan
  • AthleticoMed
    Bydgoszcz, 85-752, Poland
  • Centrum Badan Klinicznych PI-House Spzoo
    Gdansk, 80-546, Poland
  • Centrum Terapii Wspolczesnej
    Lodz, 90-338, Poland
  • AppleTreeClinics Network Spzoo
    Lodz, 90-349, Poland
  • Clinical Best Solutions Sp zoo Spolka Komandytowa
    Lublin, 20-078, Poland
  • Migre Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak
    Wroclaw, 52-210, Poland
  • Dongguk University Ilsan Hospital
    Goyang-si, Gyeonggi-do, 10326, South Korea
  • Gachon University Gil Medical Center
    Incheon, 21565, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do, 13620, South Korea
  • Kangbuk Samsung Hospital
    Seoul, 03181, South Korea
  • Hospital Vithas Sevilla
    Castilleja de la Cuesta, Andalusia 41950, Spain
  • Hospital Clinico Universitario Virgen de la Victoria
    Málaga, Andalusia 29010, Spain
  • Hospital Universitario Arnau de Vilanova Lleida
    Lleida, Catalonia 25198, Spain
  • Complexo Hospitalario Universitario A Coruña
    A Coruña, Galicia 15006, Spain
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung City, 80756, Taiwan
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 70403, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
08

References and documents

Publications

  • Jastreboff AM, Ryan DH, Bays HE, Ebeling PR, Mackowski MG, Philipose N, Ross L, Liu Y, Burns CE, Abbasi SA, Pannacciulli N; MariTide Phase 2 Obesity Trial Investigators. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025 Sep 4;393(9):843-857. doi: 10.1056/NEJMoa2504214. Epub 2025 Jun 23. PubMed 40549887 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Oct 2024, 20 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 20 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2022
First posted
Jan 3, 2023
StartActual
Jan 18, 2023
Primary completionActual
Oct 8, 2024
CompletionActual
Dec 16, 2025
Results delay requested
Feb 14, 2025
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05669599
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 3, 2023
Start date
Jan 18, 2023
Primary completion
Oct 8, 2024
Completion
Dec 16, 2025
Last update
Jan 20, 2026

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion